AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8285749 — intervention group
Group type: COMPARATOR
Intervention: Selective paralysis (synchronised ventilation with pancuronium if consistently expiring during inspiratory phase)
Number of subjects: 193
Study 8285749 — intervention group
Group type: COMPARATOR
Intervention: Selective paralysis (synchronised ventilation)
Number of subjects: 193
Study 2955253 — intervention group
Group type: EXPERIMENTAL
Intervention: Low MW heparin (Kabi 2165) administered as 5000 or 10,000 anti-factor Xa units, s.c., half an hour prior to dialysis
Number of subjects: 16
Study 2955253 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bolus injection of 5000 anti-factor Xa units of low MW heparin given i.v.
Number of subjects: 16
Study 2955253 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of low MW heparin at 5000 anti-factor Xa units bolus plus 1500 anti-factor Xa units/h
Number of subjects: 16
Study 2955253 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of low MW heparin at approximately 4000 anti-factor Xa units bolus plus 750 anti-factor Xa units/h
Number of subjects: 16
Study 12521812 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-closure of the visceral and parietal peritoneum (study open group)
Number of subjects: 66
Study 12521812 — intervention group
Group type: COMPARATOR
Intervention: Closure of the visceral and parietal peritoneum (control closed group)
Number of subjects: 66
Study 31760401 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 240
Study 29901496 — intervention group
Group type: EXPERIMENTAL
Intervention: Active low-frequency repetitive transcranial magnetic stimulation (rTMS) over bilateral presupplementary motor area (pre-SMA)
Number of subjects: 40
Study 29901496 — intervention group
Group type: COMPARATOR
Intervention: Sham low-frequency repetitive transcranial magnetic stimulation (rTMS) over bilateral presupplementary motor area (pre-SMA)
Number of subjects: 40
Study 26703923 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management programme (SPACE for COPD) consisting of an education manual and consultation
Number of subjects: 184
Study 26703923 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 184
Study 25013996 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose GH (LGH) therapy
Number of subjects: 17
Study 25013996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 22699446 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified chick embryo cell (PCECV) rabies vaccine
Number of subjects: 80
Study 22699446 — intervention group
Group type: COMPARATOR
Intervention: Purified verocell rabies vaccine (PVRV)
Number of subjects: 80
Study 20015921 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl 400 microg
Number of subjects: 27
Study 20015921 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl 100 and 200 microg
Number of subjects: 27
Study 20015921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 18809612 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis intervention (five weekly sessions)
Number of subjects: 60
Study 18809612 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 60
Study 15757817 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin sulfate ointment (15% in urea) applied twice daily for 20 days
Number of subjects: 60
Study 15757817 — intervention group
Group type: COMPARATOR
Intervention: Meglumine antimonate (1 ml intradermally every other day for 20 days)
Number of subjects: 60
Study 11828262 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (dl‐alpha‐tocopherol) 1000 mg/day for 3 months
Number of subjects: 0
Study 11828262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10049268 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting conditions (twice)
Number of subjects: 14
Study 10049268 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids (aluminum-magnesium)
Number of subjects: 14
Study 10049268 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 14
Study 7589655 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH-a) initiated in early follicular phase
Number of subjects: 5
Study 7589655 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist (GnRH-a) initiated in midluteal phase
Number of subjects: 5
Study 7589655 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH-a) initiated in late luteal phase
Number of subjects: 5
Study 2176098 — intervention group
Group type: EXPERIMENTAL
Intervention: CP buffered with sodium bicarbonate (pH 7.7)
Number of subjects: 40
Study 2176098 — intervention group
Group type: EXPERIMENTAL
Intervention: CP buffered with tromethamine (pH 7.7)
Number of subjects: 40
Study 2176098 — intervention group
Group type: COMPARATOR
Intervention: Commercial CP (pH 4.35)
Number of subjects: 40
Study 2176098 — intervention group
Group type: EXPERIMENTAL
Intervention: CP buffered with sodium bicarbonate and tromethamine (pH 7.7)
Number of subjects: 40
Study 88358 — intervention group
Group type: EXPERIMENTAL
Intervention: Large VEP amplitude with large ERD
Number of subjects: 10
Study 88358 — intervention group
Group type: COMPARATOR
Intervention: Small VEP amplitude with small ERD
Number of subjects: 10
Study 31701170 — intervention group
Group type: EXPERIMENTAL
Intervention: TPEx regimen (docetaxel, cisplatin, and cetuximab)
Number of subjects: 0
Study 31701170 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab, 5‑FU, and cis-/carboplatin
Number of subjects: 0
Study 31701170 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy (for selected patients with PD-L1 CPS ≥1 and ≥20)
Number of subjects: 0
Study 31701170 — intervention group
Group type: COMPARATOR
Intervention: Extreme regimen (cisplatin, 5‑fluorouracil [5‐FU], cetuximab)
Number of subjects: 0
Study 30580857 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 100
Study 27146582 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial biopsy using a Pipelle catheter combined with intrauterine insemination
Number of subjects: 360
Study 27146582 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine insemination without endometrial biopsy
Number of subjects: 360
Study 24682081 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 89
Study 24682081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 24682081 — intervention group
Group type: COMPARATOR
Intervention: Naloxone
Number of subjects: 89
Study 21984060 — intervention group
Group type: EXPERIMENTAL
Intervention: One stage-modified transmastoid approach for surgical repair
Number of subjects: 33
Study 20665349 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger cane users
Number of subjects: 32
Study 20665349 — intervention group
Group type: COMPARATOR
Intervention: Older cane users
Number of subjects: 32
Study 20665349 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger participants
Number of subjects: 32
Study 20665349 — intervention group
Group type: COMPARATOR
Intervention: Older participants
Number of subjects: 32
Study 20665349 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-onset visual impairment
Number of subjects: 32
Study 20665349 — intervention group
Group type: COMPARATOR
Intervention: Later-onset visual impairment
Number of subjects: 32
Study 17868011 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment over a 6-week course
Number of subjects: 0
Study 17868011 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic drug treatment over a 6-month period
Number of subjects: 0
Study 15892268 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) intervention
Number of subjects: 0
Study 15892268 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatments
Number of subjects: 0
Study 15892268 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 14719294 — intervention group
Group type: EXPERIMENTAL
Intervention: Huo Nao Fang
Number of subjects: 120
Study 14719294 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 120
Study 10808977 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored telephone counseling
Number of subjects: 1099
Study 10808977 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored print communications
Number of subjects: 1099
Study 10808977 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1099
Study 8972953 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anaesthetic EMLA cream
Number of subjects: 100
Study 8972953 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic nerve stimulation
Number of subjects: 100
Study 1479198 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hyperthermia (HT) and radiation therapy (XRT)
Number of subjects: 0
Study 6428504 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 35% carbon dioxide and 65% oxygen
Number of subjects: 0
Study 6428504 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 35% carbon dioxide and 65% oxygen preceded by 60 mg propranolol
Number of subjects: 0
Study 6428504 — intervention group
Group type: COMPARATOR
Intervention: Placebo (air)
Number of subjects: 0
Study 30839256 — intervention group
Group type: EXPERIMENTAL
Intervention: InMotion 3.0 (IMT)
Number of subjects: 30
Study 30839256 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-Manu-Track (BMT)
Number of subjects: 30
Study 30839256 — intervention group
Group type: COMPARATOR
Intervention: Control Treatment (CT)
Number of subjects: 30
Study 29225020 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic Wafer Procedure (AWP)
Number of subjects: 42
Study 29225020 — intervention group
Group type: COMPARATOR
Intervention: Ulnar Shortening Osteotomy (USO)
Number of subjects: 42
Study 27611236 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to an iPad containing additional information about breast cancer (13 women)
Number of subjects: 39
Study 27611236 — intervention group
Group type: COMPARATOR
Intervention: Control group without access to the iPad information (26 women)
Number of subjects: 39
Study 24660799 — intervention group
Group type: EXPERIMENTAL
Intervention: Martial artists (black belt)
Number of subjects: 143
Study 24660799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sportive individuals (without explicit balance components)
Number of subjects: 143
Study 24660799 — intervention group
Group type: COMPARATOR
Intervention: Nonsportive controls
Number of subjects: 143
Study 22759936 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy
Number of subjects: 0
Study 22759936 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Therapy
Number of subjects: 0
Study 22759936 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy
Number of subjects: 0
Study 20491718 — intervention group
Group type: EXPERIMENTAL
Intervention: Iterative hypothesis testing (IHT)
Number of subjects: 72
Study 20491718 — intervention group
Group type: COMPARATOR
Intervention: Problem-based learning
Number of subjects: 72
Study 18588702 — intervention group
Group type: EXPERIMENTAL
Intervention: FairMed
Number of subjects: 60
Study 18588702 — intervention group
Group type: COMPARATOR
Intervention: TENS
Number of subjects: 60
Study 15978969 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT with Presomen (1.25mg equine conjugated estrogens for 21 days + 5mg medrogeston for 11 days)
Number of subjects: 48
Study 15978969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 11821275 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (15 +/- 1.5 mm)
Number of subjects: 180
Study 11821275 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (20 +/- 1.5 mm)
Number of subjects: 180
Study 11821275 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (10 +/- 1.5 mm)
Number of subjects: 180
Study 9540025 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol (50 or 100 mg t.i.d.)
Number of subjects: 345
Study 9540025 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol
Number of subjects: 345
Study 9540025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 345
Study 8294388 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined SSRI (sertraline or fluvoxamine) with moclobemide
Number of subjects: 11
Study 8294388 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (150 to 800 mg/day) with sertraline (25 to 200 mg/day)
Number of subjects: 11
Study 8294388 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (150 to 800 mg/day) with fluvoxamine (50 to 200 mg/day)
Number of subjects: 11
Study 2660873 — intervention group
Group type: EXPERIMENTAL
Intervention: Sultamicillin (375 mg)
Number of subjects: 38
Study 2660873 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole (160 mg/800 mg)
Number of subjects: 38
Study 2660873 — intervention group
Group type: EXPERIMENTAL
Intervention: Sultamicillin
Number of subjects: 38
Study 2660873 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole
Number of subjects: 38
Study 4261553 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectinomycin 2 g
Number of subjects: 667
Study 4261553 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectinomycin 4 g
Number of subjects: 667
Study 4261553 — intervention group
Group type: COMPARATOR
Intervention: Procaine penicillin 2.4 million units (males)
Number of subjects: 667
Study 4261553 — intervention group
Group type: COMPARATOR
Intervention: Procaine penicillin 4.8 million units (females)
Number of subjects: 667
Study 4261553 — intervention group
Group type: COMPARATOR
Intervention: Procaine penicillin 2.4 million units (females)
Number of subjects: 667
Study 31091748 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention with partial meal replacement
Number of subjects: 211
Study 29283688 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein extracts from medium of Adipose-derived stem cells (ADSCs) via microneedles
Number of subjects: 30
Study 29283688 — intervention group
Group type: COMPARATOR
Intervention: Ultrapure water
Number of subjects: 30
Study 27687405 — intervention group
Group type: EXPERIMENTAL
Intervention: High pillow (HP) group
Number of subjects: 50
Study 27687405 — intervention group
Group type: COMPARATOR
Intervention: Low pillow (LP) group
Number of subjects: 50
Study 24885005 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based feedback of public oral presentations
Number of subjects: 142
Study 24885005 — intervention group
Group type: COMPARATOR
Intervention: Classical oral presentations without feedback (Control)
Number of subjects: 142
Study 22500387 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzheng Yiliu Recipe (FYR) combined with microwave ablation
Number of subjects: 60
Study 22500387 — intervention group
Group type: COMPARATOR
Intervention: Microwave ablation
Number of subjects: 60
Study 20187877 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation for 2 years
Number of subjects: 109
Study 20187877 — intervention group
Group type: COMPARATOR
Intervention: Control group (LBW-T)
Number of subjects: 109
Study 17962424 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol controlled-release 40 mg with ethanol (approximately 38 g)
Number of subjects: 39
Study 17962424 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol controlled-release alone
Number of subjects: 39
Study 17962424 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol controlled-release with ethanol 2 hours after administration
Number of subjects: 39
Study 17962424 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol controlled-release alone or with ethanol
Number of subjects: 39
Study 16236169 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-naïve atopic asthmatic children
Number of subjects: 82
Study 16236169 — intervention group
Group type: COMPARATOR
Intervention: Atopic nonasthmatic children
Number of subjects: 82
Study 16236169 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic asthmatic children receiving inhaled corticosteroids
Number of subjects: 82
Study 16236169 — intervention group
Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 82
Study 12404872 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of antivenom
Number of subjects: 275
Study 12404872 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 to 5 ml of antivenom
Number of subjects: 275
Study 12404872 — intervention group
Group type: COMPARATOR
Intervention: No antivenom administration
Number of subjects: 275
Study 9464716 — intervention group
Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy (TLH)
Number of subjects: 143
Study 9464716 — intervention group
Group type: COMPARATOR
Intervention: Total abdominal hysterectomy (TAH)
Number of subjects: 143
Study 8563848 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinusoidal vibration (125 Hz, 87.5 m.s‐2 rms) for 30 minutes on the right hand
Number of subjects: 8
Study 8563848 — intervention group
Group type: COMPARATOR
Intervention: Static load (10 N) without vibration
Number of subjects: 8
Study 2697725 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% fusidic acid viscous eye drops, instilled twice daily for 7 days
Number of subjects: 163
Study 2697725 — intervention group
Group type: COMPARATOR
Intervention: rifamycin eye drops, four times daily for 7 days
Number of subjects: 163
Study 12484 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxypertine (10 mg every 12 hours, 20 mg daily)
Number of subjects: 30
Study 12484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12484 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxypertine after placebo (group III)
Number of subjects: 30
Study 12484 — intervention group
Group type: COMPARATOR
Intervention: Placebo after oxypertine (group III)
Number of subjects: 30
Study 7104467 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional 4 mg tablet administered every 6 hours
Number of subjects: 15
Study 7104467 — intervention group
Group type: COMPARATOR
Intervention: Controlled release 8 mg barrier coated-bead capsule administered every 12 hours
Number of subjects: 15
Study 7104467 — intervention group
Group type: COMPARATOR
Intervention: Controlled release 8 mg repeat action tablet administered every 12 hours
Number of subjects: 15
Study 31269007 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 44
Study 31269007 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 44
Study 31269007 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 44
Study 29103414 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening (up to 60 min) with routine care
Number of subjects: 35
Study 29103414 — intervention group
Group type: COMPARATOR
Intervention: Routine care with no music
Number of subjects: 35
Study 25853935 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (levosimendan + nesiritide)
Number of subjects: 120
Study 24415446 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (NORDIET) for 6 weeks
Number of subjects: 1979
Study 24415446 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year follow-up
Number of subjects: 1979
Study 24415446 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1979
Study 23200590 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary non-invasive ventilation in addition to long-term oxygen therapy (LTOT)
Number of subjects: 100
Study 23200590 — intervention group
Group type: COMPARATOR
Intervention: Long-term oxygen therapy (LTOT)
Number of subjects: 100
Study 18384995 — intervention group
Group type: EXPERIMENTAL
Intervention: iomeprol 400
Number of subjects: 80
Study 18384995 — intervention group
Group type: COMPARATOR
Intervention: iodixanol 320
Number of subjects: 80
Study 17514706 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic play
Number of subjects: 203
Study 17514706 — intervention group
Group type: COMPARATOR
Intervention: Routine information preparation (Control)
Number of subjects: 203
Study 15342839 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment, 33 microg/kg/day for 3 years
Number of subjects: 87
Study 15342839 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 87
Study 11180040 — intervention group
Group type: EXPERIMENTAL
Intervention: ADL 8-2698 (4 mg) with intravenous morphine (0.05 mg x kg(‐1))
Number of subjects: 59
Study 11180040 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine (0.05 mg x kg(‐1))
Number of subjects: 59
Study 11180040 — intervention group
Group type: EXPERIMENTAL
Intervention: ADL 8-2698 (4 mg) with intravenous morphine (0.15 mg/kg)
Number of subjects: 59
Study 11180040 — intervention group
Group type: COMPARATOR
Intervention: Placebo with intravenous morphine (0.15 mg/kg)
Number of subjects: 59
Study 9895052 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave lithotripsy (ESWL)
Number of subjects: 92
Study 9895052 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical lithotripsy (ML)
Number of subjects: 92
Study 9895052 — intervention group
Group type: COMPARATOR
Intervention: Overall (both groups)
Number of subjects: 92
Study 8043892 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion for improvement of glycaemic control
Number of subjects: 21
Study 8043892 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced insulin dose
Number of subjects: 21
Study 8043892 — intervention group
Group type: COMPARATOR
Intervention: Increased insulin dose
Number of subjects: 21
Study 3054433 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (500 kcal/d)
Number of subjects: 15
Study 3054433 — intervention group
Group type: COMPARATOR
Intervention: Insulin treatment
Number of subjects: 15
Study 4951237 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 48
Study 31178499 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence for phosphate binders
Number of subjects: 524
Study 31178499 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence for antidiabetic medications
Number of subjects: 524
Study 31178499 — intervention group
Group type: EXPERIMENTAL
Intervention: Reason for missed dose
Number of subjects: 524
Study 31178499 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference for oral medication (mental burden present)
Number of subjects: 524